Drugs Like Lemtrada May Benefit MS Patients Right From The Start

Lemtrada Stroke Lawsuit News

An Italian study indicates Lemtrada may be more effective than other drugs if treatments begin early.

Tuesday, September 29, 2020 - About three million people are living with multiple sclerosis today. Most cases of multiple sclerosis begin around the age of 30. There are approximately 30,000 cases of MS in people under 18 years old worldwide. The disease progresses from mild to severe over time. There is currently no drug on the market to stop it. MS is not a fatal disease, but one that eventually can lead to permanent disability due to muscle spasticity. Those with multiple sclerosis say that it is a disease that one dies with, not dies from. Lemtrada is considered the drug of last resort for treating those with the advanced stages of the disease. Lemtrada treatments are to be considered only when all others have failed.

Lemtrada intravenous infusion is given to patients in two treatments, one for five days, and the other for three days, one year apart. Lemtrada toxicity includes a warning that people have experienced sudden death and permanent paralysis from having a heart attack or stroke during or shortly after a Lemtrada infusion. The US Food and Drug Administration requires that both Lemtrada patients and their doctors complete and sign a questionnaire attesting that they understand: "serious cases of stroke and tears in the lining of arteries in the head and neck have occurred in patients with multiple sclerosis (MS) shortly after they received Lemtrada (alemtuzumab). These problems can lead to permanent disability and even death."

Lemtrada lawsuits are handled by top national attorneys and offer a free no obligation consultation before filing a claim.

In the past, patients with RRMS and their doctors put off more intense and potentially hazardous treatments with drugs like Lemtrada, preferring to treat the disease with milder disease-modifying therapy (DMT) drugs initially. New studies indicate, however, that taking a step-by-step approach to taking ever more potent drugs as the disease progresses may not be the best course of action for some patients. Multiple Sclerosis News Today writes, "Early use of high efficacy disease-modifying therapies (DMTs) is more effective than the traditional approach - that of an escalating treatment regimen - at delaying disability progression in people with relapsing-remitting multiple sclerosis (RRMS), a real-life study from Italy reports. People later moving to more aggressive treatment also appeared to benefit less from it than those treated intensively from the start, its researchers said." Multiple Sclerosis doctors today are divided as to how aggressively to treat the disease given the profound safety profiles of more effective medicines like Truvada. Truvada carries the most severe FDA black box warning stating that the drug itself could be much more deadly than the disease it is intended to treat. In addition to instant death and paralysis, the Lemtrada homepage highlights such serious side effects as autoimmune difficulties where the cells that make up the immune system attack themselves and also may attack vital organs in the body. Blood clotting issues have been reported also, "a condition of reduced platelet counts in your blood that can cause severe bleeding that may cause life‑threatening problems."

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.